Nomura Holdings Inc Editas Medicine, Inc. Transaction History

Nomura Holdings Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$8.32 - $13.21 $137,280 - $217,965	16,500 Added 44.66%	53,444 $474,000
Q2 2022 Aug 15, 2022	BUY	$9.99 - $21.35 $174,265 - $372,429	17,444 Added 89.46%	36,944 $465,000
Q1 2022 May 18, 2022	BUY	$14.08 - $27.63 $126,565 - $248,366	8,989 Added 85.52%	19,500 $394,000
Q4 2021 Feb 14, 2022	BUY	$26.55 - $40.57 $279,067 - $426,431	10,511 New	10,511 $279,000
Q3 2021 Nov 15, 2021	SELL	$39.27 - $72.94 $245,437 - $455,875	-6,250 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$31.29 - $56.64 $31,290 - $56,640	-1,000 Reduced 13.79%	6,250 $355,000
Q1 2021 May 17, 2021	BUY	$39.71 - $90.58 $287,897 - $656,705	7,250 New	7,250 $304,000

248

57M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Nomura Holdings Inc, based on Form 13F filings with the SEC.

Stay updated on Nomura Holdings Inc with notifications on news.